Bank of America
FDMT icon

Bank of America’s 4D Molecular Therapeutics FDMT Stock Holding History

Bank of America’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9M Buy
1,120,674
+146,501
+15% +$1.43M ﹤0.01% 2737
2026
Q1 		$9.07M Buy
974,173
+141,582
+17% +$1.23M ﹤0.01% 3039
2025
Q4 		$6.24M Buy
832,591
+13,325
+2% +$135K ﹤0.01% 3208
2025
Q3 		$7.12M Sell
819,266
-77,804
-9% -$465K ﹤0.01% 3656
2025
Q2 		$3.33M Buy
897,070
+198,762
+28% +$699K ﹤0.01% 4301
2025
Q1 		$2.26M Buy
698,308
+313,428
+81% +$1.48M ﹤0.01% 4581
2024
Q4 		$2.14M Buy
384,880
+116,024
+43% +$910K ﹤0.01% 4382
2024
Q3 		$2.91M Buy
268,856
+41,257
+18% +$685K ﹤0.01% 4236
2024
Q2 		$4.78M Buy
227,599
+108,042
+90% +$2.71M ﹤0.01% 3667
2024
Q1 		$3.81M Sell
119,557
-45,799
-28% -$1.17M ﹤0.01% 3870
2023
Q4 		$3.35M Buy
165,356
+27,826
+20% +$366K ﹤0.01% 3904
2023
Q3 		$1.75M Buy
137,530
+35,022
+34% +$586K ﹤0.01% 4382
2023
Q2 		$1.85M Sell
102,508
-90,375
-47% -$1.66M ﹤0.01% 4293
2023
Q1 		$3.32M Buy
192,883
+115,471
+149% +$2.25M ﹤0.01% 3918
2022
Q4 		$1.72M Buy
77,412
+57,509
+289% +$888K ﹤0.01% 4391
2022
Q3 		$160K Sell
19,903
-2,044
-9% -$18.5K ﹤0.01% 6111
2022
Q2 		$153K Sell
21,947
-86,033
-80% -$836K ﹤0.01% 6264
2022
Q1 		$1.63M Buy
107,980
+20,533
+23% +$322K ﹤0.01% 4790
2021
Q4 		$1.92M Buy
87,447
+74,824
+593% +$1.83M ﹤0.01% 4608
2021
Q3 		$341K Buy
12,623
+1,608
+15% +$45.9K ﹤0.01% 5924
2021
Q2 		$265K Buy
11,015
+4,138
+60% +$127K ﹤0.01% 5884
2021
Q1 		$297K Buy
6,877
+6,837
+17,093% +$303K ﹤0.01% 5751
2020
Q4 		$2K Buy
+40
New +$1.65K ﹤0.01% 6936

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Bank of America's FDMT Position: Q2 2026 in Review

Bank of America increased its 4D Molecular Therapeutics (FDMT) stake by 15% in Q2 2026, buying an estimated $1.43M and bringing the position to 1,120,674 shares worth $14.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2737.

Bank of America first reported a position in FDMT in Q4 2020 and has held it in 23 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Bank of America held 1,120,674 shares of 4D Molecular Therapeutics worth $14.9M as of Q2 2026.
  • Bank of America bought 146,501 4D Molecular Therapeutics shares in Q2 2026, an estimated $1.43M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #2737 holding.
  • Bank of America first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.